Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 3067.

https://doi.org/10.1182/blood.V128.22.3067.3067

Published: 2016

Journal Articles

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

Laura N Eadie, PhD, Jarrad M Goyne, BMedSc (Hons), Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Deborah L White, PhD FFSc (RCPA)

Blood (2016) 128 (22): 4237.

https://doi.org/10.1182/blood.V128.22.4237.4237

Published: 2016

Journal Articles

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

Kartini Asari, Susan L Heatley, PhD MD, Teresa Sadras, PhD, Tamara M Leclercq, PhD, Stephen Fitter, PhD, Chung Hoow Kok, PhD, Andrew C W Zannettino, PhD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, Deborah L White, PhD FFSc (RCPA)

Blood (2016) 128 (22): 3957.

https://doi.org/10.1182/blood.V128.22.3957.3957

Published: 2016

Journal Articles

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

Naranie Shanmuganathan, MBBS, FRACP, FRCPA, Susan Branford, PhD FFSc (RCPA), Jodi Braley, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1890.

https://doi.org/10.1182/blood.V128.22.1890.1890

Published: 2016

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Blood (2016) 128 (22): 1891.

https://doi.org/10.1182/blood.V128.22.1891.1891

Published: 2016

Journal Articles

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Amy Hughes, PhD, Jade Clarson, B.Sc, Deborah L White, PhD FFSc (RCPA), David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Agnes S Yong, MD PhD

Blood (2016) 128 (22): 1122.

https://doi.org/10.1182/blood.V128.22.1122.1122

Published: 2016

Journal Articles

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Justine E Marum, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Martin C. Mueller, Christian T. Dietz, PhD, Ieuan Walker, MSc, BSc, MBBS, Nathalie Nataren, BSc, Zoe Donaldson, BSc, Wendy T Parker, PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Andreas W Schreiber, PhD, Susan Branford, PhD FFSc (RCPA)

Blood (2016) 128 (22): 1219.

https://doi.org/10.1182/blood.V128.22.1219.1219

Published: 2016

Journal Articles

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Verity A Saunders, BSc (Hons), Jueqiong Wang, PhD, Liu Lu, PhD, Laura N Eadie, PhD, Jennifer A McLean, Jarrad M Goyne, BMedSc (Hons), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1121.

https://doi.org/10.1182/blood.V128.22.1121.1121

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Carla Maria Boquimpani, Naoto Takahashi, MD PhD, Noam Benyamini, MD, Nelma Cristina D Clementino, MD, Vasily Shuvaev, MD, Sikander Ailawadhi, MD, Jeffrey H. Lipton, MD PhD, Anna G Turkina, Prof., MD, Elena Beatriz Moiraghi, MD, Franck E. Nicolini, MD PhD, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, MD PhD, Rafik Fellague-Chebra, MD MSc, Sandip Acharya, MSc, Nancy Krunic, PhD, Yu Jin, MS, François-Xavier Mahon, MD PhD

Blood (2016) 128 (22): 792.

https://doi.org/10.1182/blood.V128.22.792.792

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only